NVI-100
Acute Treatment of Migraine
Phase 1Active
Key Facts
About Nuvie Bio
Nuvie Bio is a private, clinical-stage biotech focused on transforming the acute treatment of migraine through a proprietary peptide platform. Its lead candidate, NVI-100, is a first-in-class, water-soluble peptide CGRP receptor antagonist designed for rapid subcutaneous administration via an autoinjector. The company aims to address the significant unmet need for a treatment that combines speed, high efficacy, and minimal adverse events, positioning itself in the competitive but growing migraine therapeutics market. Nuvie Bio is led by a team with deep expertise in neuroscience, peptide therapeutics, and migraine drug development.
View full company profileOther Acute Treatment of Migraine Drugs
| Drug | Company | Phase |
|---|---|---|
| Elismetrep (K-304) | Kallyope | Phase 2 |
| RizaFilm® (RizaPort®) | Gensco Pharma | Approved/Pre-launch |
| ONZETRA Xsail | Currax Pharmaceuticals | Approved |
| TREXIMET | Currax Pharmaceuticals | Approved |
| Nerivio | Theranica | Approved |
| gammaCore | electroCore | Commercial |